Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study

Blood (2025) 146 (Supplement 1): 2778.

https://doi.org/10.1182/blood-2025-2778

Published: 2025

Journal Articles

Transcriptomic signatures associated with deep molecular response to ropeginterferon alfa-2b in polycythemia vera

Seug Yun Yoon, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won June-Won, Soo-Mee Bang, Joon Seong Park, Yong Park, Young Hoon Park, Sung-Eun Lee

Blood (2025) 146 (Supplement 1): 2040.

https://doi.org/10.1182/blood-2025-2040

Published: 2025

Journal Articles

Clinical significance of earlier CHR achievement and long-term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa-2b

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Jong Wook Lee, Yong Park, Young Hoon Park

Blood (2025) 146 (Supplement 1): 5598.

https://doi.org/10.1182/blood-2025-5598

Published: 2025

Journal Articles

Rapid JAK2 V617F decline predicts response durability: Kinetics of JAK2 V617F in ropeginterferon alfa-2b treated polycythemia vera

Blood (2025) 146 (Supplement 1): 3819.

https://doi.org/10.1182/blood-2025-3819

Published: 2025

Journal Articles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Blood (2024) 144 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2024-202823

Published: 2024

Journal Articles

Ropeginterferon in Low-Risk Patients with Polycythemia Vera

Ji Yun Lee, Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Sang Kyun Sohn, Seug Yun Yoon, Soo-Mee Bang, Gyeong Won Lee, Chul Won Choi, Yunsuk Choi, June-Won Cheong, Young Hoon Park

Blood (2024) 144 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2024-202345

Published: 2024

Journal Articles

Distinct Factors Influence on Complete Hematological Response Maintenance in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b: From a Phase 2 Study in South Korea

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 6673.

https://doi.org/10.1182/blood-2024-206881

Published: 2024

Journal Articles

Refining Symptom Response Criteria in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 6642.

https://doi.org/10.1182/blood-2024-206509

Published: 2024

Journal Articles

Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

Seug Yun Yoon, Jong-Ho Won, Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Yunsuk Choi, June-won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2024) 144 (Supplement 1): 3170.

https://doi.org/10.1182/blood-2024-207042

Published: 2024

Journal Articles

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong Won Lee, Seug Yun Yoon, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park, Sukjoong Oh, Yong Park, Young Hoon Park

Blood (2023) 142 (Supplement 1): 4575.

https://doi.org/10.1182/blood-2023-184431

Published: 2023

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Journal Articles

Pigment Epithelium-Derived Factor Promotes the Angiogenic Activity of VEGF

Jeong-A Kim, MD PhD, Misuk Yang, Young Hoon Park, MD, Youngrok Park, Jae-Yong Kwak, MD PhD

Blood (2018) 132 (Supplement 1): 3687.

https://doi.org/10.1182/blood-2018-99-117420

Published: 2018

Journal Articles

Biologic Features and Clinical Outcomes According to Age Groups In Myelodysplastic Syndrome

Seungbum Lee, M.D., Je-Hwan Lee, Jung-Hee Lee, Dae-Young Kim, Sung-Doo Kim, MD, Sung-Nam Lim, M.D., Yunsuk Choi, MD, Young-Hoon Park, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Kyoo-Hyung Lee, M.D., PhD.

Blood (2010) 116 (21): 4963.

https://doi.org/10.1182/blood.V116.21.4963.4963

Published: 2010

Journal Articles

Survival Advantage with Hypomethylating Agents In Patients with Higher Risk Myelodysplastic Syndrome

Young-Hoon Park, Je-Hwan Lee, Kyoo Hyung Lee, Jung-Hee Lee, Dae-Young Kim, Sung-Doo Kim, MD, Sung-Nam Lim, M.D., Yunsuk Choi, MD, Miee Seol, Young-Shin Lee, Young-A Kang, Mijin Jeon

Blood (2010) 116 (21): 1859.

https://doi.org/10.1182/blood.V116.21.1859.1859

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Treatment patterns and survival outcomes in patients with Mantle Cell Lymphoma: Interim report of the Asia-Pacific multinational prospective registry study

Transcriptomic signatures associated with deep molecular response to ropeginterferon alfa-2b in polycythemia vera

Clinical significance of earlier CHR achievement and long-term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa-2b

Rapid JAK2 V617F decline predicts response durability: Kinetics of JAK2 V617F in ropeginterferon alfa-2b treated polycythemia vera

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Ropeginterferon in Low-Risk Patients with Polycythemia Vera

Distinct Factors Influence on Complete Hematological Response Maintenance in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b: From a Phase 2 Study in South Korea

Refining Symptom Response Criteria in Polycythemia Vera Patients Treated with Ropeginterferon Alfa-2b

Predicting Molecular Response through Half Reduction of Neutrophil-to-Lymphocyte Ratio (NLR) in Polycythemia Vera Treatment with Ropeginterferon

A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit: Results from 12-Month Core Study

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Pigment Epithelium-Derived Factor Promotes the Angiogenic Activity of VEGF

Biologic Features and Clinical Outcomes According to Age Groups In Myelodysplastic Syndrome

Survival Advantage with Hypomethylating Agents In Patients with Higher Risk Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only